−Removed: Unregistered Sales of Equity Securities and Use of Proceeds.
+Added: Unregistered Sales of Equit y Securities and Use of Proceeds.
Use of Proceeds from Registered Securities
3 unchanged sentences
333-213469), as amended, and the final prospectus dated September 28, 2016 included in such registration statement, or the Prospectus.
−Removed: To date, we have used $7.1 million of the net proceeds from the IPO, of which, $3.1 million was used for contributions to our joint venture, FF Gene Biotech, in partial satisfaction of our contribution obligations under the cooperation agreement for the joint venture, and $4.0 million to fund the Company’s operations.
−Removed: All other net proceeds from the IPO are invested in short-term, investment-grade, interest-bearing securities, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S.
+Added: To date, we have used $9.8 million of the net proceeds from the IPO, of which, $3.1 million was used for contributions to our joint venture, FF Gene Biotech, in partial satisfaction of our contribution obligations under the cooperation agreement for the joint venture, $1.4 million was used to purchase equipment that will be contributed to FF Gene Biotech, and $5.3 million was used to fund the Company’s operations.
+Added: All other net proceeds from the IPO are invested in investment-grade and interest-bearing securities, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S.
There has been no material change in the planned use of proceeds from the IPO from that described in the Prospectus.
−Removed: On August 30 2019, we entered into an Equity Distribution Agreement with Piper Sandler & Co.
−Removed: (“Piper”) as sales agent, pursuant to which we may, from time to time, sell through Piper shares of our common stock with an aggregate purchase price of up to $30.0 million.
−Removed: During the three months ended March 31, 2020, the Company did not sell any shares of its common stock pursuant to the Equity Distribution Agreement.
+Added: On August 30 2019, we entered into the Equity Distribution Agreement with Piper as sales agent which was amended on August 4, 2020, pursuant to which we may, from time to time, sell through Piper shares of our common stock with an aggregate purchase price of up to $44.9 million.
+Added: During the three months ended June 30, 2020, the Company did not sell any shares of its common stock pursuant to the Equity Distribution Agreement.
Shares sold under the Equity Distribution Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No.
333-233227) filed with the SEC on August 12, 2019 and declared effective on August 23, 2019, and a prospectus supplement and accompanying base prospectus filed with the Securities and Exchange Commission on August 30, 2019.
−Removed: In addition, on November 13, 2019 we entered into a Purchase Agreement with Piper.
−Removed: as representative of the several underwriters, pursuant to which we sold 2,673,750 shares of our common stock at a price of $10.51875 per share, with a public offering price of $11.25 per share.
+Added: There has been no material change in the planned use of proceeds as described in the prospectus supplement and accompanying base prospectus.
+Added: In addition, on November 13, 2019 we entered into a Purchase Agreement with Piper, as representative of the several underwriters, pursuant to which we sold 2,673,750 shares of our common stock at a price of $10.51875 per share, with a public offering price of $11.25 per share.
We received net proceeds of approximately $27.6 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $2.4 million.
1 unchanged sentence
333-233227), as amended, and a prospectus supplement and accompanying base prospectus filed with the Securities and Exchange Commission on November 13, 2019.
−Removed: The information required by this Item 6 is set forth on the Exhibit Index that immediately precedes the signature page to this report and is incorporated herein by reference.
−Removed: EXHIBIT INDEX
−Removed: Incorporated by
−Removed: Exhibit Title
−Removed: Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: XBRL Instance Document
−Removed: XBRL Taxonomy Extension Schema Document
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: XBRL Definition Linkbase Document
−Removed: XBRL Taxonomy Extension Labels Linkbase Document
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: Filed herewith.
−Removed: Furnished herewith.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: FULGENT GENETICS, INC.
−Removed: /s/ Ming Hsieh
−Removed: President, Chief Executive Officer
−Removed: (principal executive officer)
−Removed: Chief Financial Officer
−Removed: (principal financial and accounting officer)
+Added: There has been no material change in the planned use of proceeds as described in the prospectus supplement and accompanying base prospectus.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.